MSCM
NVCR icon

McElhenny Sheffield Capital Management’s NovoCure NVCR Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-656
Closed -$32.3K – 433
2022
Q4 		$32.3K Buy
+656
New +$49.4K 0.02% 217

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

McElhenny Sheffield Capital Management's NVCR Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 656 shares — an estimated $32.3K sold.

McElhenny Sheffield Capital Management first reported a position in NVCR in Q4 2022 and held it in 1 quarter. The position peaked at $32.3K in Q4 2022. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 656 NovoCure shares in Q1 2023, an estimated $32.3K.
  • McElhenny Sheffield Capital Management first reported a position in NovoCure in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's NovoCure position peaked at $32.3K in Q4 2022.
  • 295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.